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Structured interventions on lifestyle have been suggested as a cost-eﬀective strategy for prevention of cardiovascular disease.
Epidemiologic studies demonstrate that dietary salt restriction eﬀectively decreases blood pressure, but its inﬂuence on
cardiovascular morbidity and mortality is still under debate. Evidence gathered from studies conducted in patients with primary
aldosteronism, essential hypertension, or heart failure demonstrates that long-term exposure to elevated aldosterone results in
cardiac structural and functional changes that are independent of blood pressure. Animal experiments and initial clinical studies
indicate that aldosterone damages the heart only in the context of an inappropriately elevated salt status. Recent evidence
suggests that aldosterone might functionally interact with the parathyroid hormone and thereby aﬀect calcium homeostasis with
important sequelae for bone mineral density and strength. The interaction between aldosterone and parathyroid hormone might
have implications also for the heart. Elevated dietary salt is associated on the one hand with increased urinary calcium excretion
and, on the other hand, could facilitate the interaction between aldosterone and parathyroid hormone at the cellular level. This
review summarizes the evidence supporting the contribution of salt and aldosterone to cardiovascular disease and the possible
cardiac and skeletal consequences of the mutual interplay between aldosterone, parathyroid hormone, and salt.
1. Introduction
Arterial hypertension is the most frequent modiﬁable cardio-
vascular risk factor. The NHANES (National Health and
Nutrition Examination Survey) has estimated a prevalence
of hypertension of 30% among the adult population, and that
approximately 85% of people between 55 and 65 years will
develop hypertension within their lifetime [1]. Because blood
pressure control in the population is a diﬃcult task, preven-
tion and treatment of hypertension through interventions
on patients’ lifestyle have been suggested as a cost-eﬀective
strategy [2–4]. Among these interventions, a reduction of
dietary salt intake could be beneﬁcial for blood pressure con-
trol and prevention of heart failure [5].
Evidence gathered in the last decades indicates that, in
addition to the well-known renal tubular actions, aldoste-
rone regulates many cellular functions. These cellular
eﬀects of aldosterone result in the regulation of speciﬁc
responses including tissue remodeling, hypertrophy, and
ﬁbrosis [6]. In fact, chronic exposure to aldosterone levels
that are inappropriately elevated for the salt status causes
cardiovascular damage independent of blood pressure [7].
Past animal experiments reported that chronic exposure
to elevated aldosterone causes myocardial ﬁbrosis in rats
that are maintained on a high-salt diet [8] and that these
changes are prevented by either administration of aldoste-
rone antagonists or adrenalectomy [9]. In addition to these
animal data, studies conducted in patients with primary
aldosteronism [10] or essential hypertension [11] provided
evidence that long-term exposure to inappropriately ele-
vated aldosterone leads to a variety of organ sequelae
occurring beyond what could be expected from the
increase in blood pressure. Also, indirect evidence of the
untoward eﬀects of aldosterone on the cardiovascular
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system was obtained in clinical studies that investigated
the eﬀects of either aldosterone antagonists or adrenalec-
tomy on patients with primary aldosteronism [10, 12].
Increasing evidence indicates that, beyond its cardio-
vascular eﬀects, aldosterone excess might aﬀect also min-
eral metabolism and have speciﬁc relevance for calcium
homeostasis [13–15]. Because primary hyperparathyroid-
ism is associated with poor cardiovascular outcome, a role
in cardiovascular disease has been attributed also to the
parathyroid hormone (PTH) [13–15]. Recent studies have
demonstrated a reciprocal interaction between aldosterone
and PTH, and there is growing evidence that the salt
status might have a role within this interaction. This inter-
action between aldosterone and PTH could have clinical
relevance because it could lead, on the one hand, to
cardiac structural and functional changes that facilitate
development and progression of heart failure and, on the
other hand, to decreased bone mineral density and
strength. In this narrative review, we outline the evidence
supporting the contribution of salt and aldosterone to
cardiovascular disease and the possible consequences of
the mutual interplay between salt, aldosterone, and PTH
on cardiac and skeletal damage.
2. The Role of Salt
The association between dietary salt consumption, hyperten-
sion, and cardiovascular disease has long been the subject of
important epidemiological studies. Because of signiﬁcant
discrepancies among the ﬁndings of these studies, this
association remains under debate [16].
2.1. Dietary Salt and Blood Pressure. Dietary salt consump-
tion has long been associated with blood pressure regulation.
In fact, hypertensive patients have been classiﬁed as “salt-
resistant” or “salt-sensitive” depending upon their blood
pressure response to an oral or intravenous salt load. Salt is
distributed in the extracellular ﬂuid and, as such, participates
in blood pressure regulation [17]. The eﬀects of salt on blood
pressure, however, can be attributed to changes in extracellu-
lar volume only in part, and additional mechanisms might be
involved, including changes in vascular responses to vasoac-
tive substances and interaction with a variety of hormonal
systems [18].
The relationship between dietary salt intake and blood
pressure was initially investigated in the International Study
of Salt and Blood Pressure (INTERSALT) population study
[19]. This study demonstrated that populations with high salt
intake had higher blood pressure and a greater age-related
blood pressure increase than populations with low salt
intake. Although prevalence of hypertension in populations
with low salt consumption was unremarkable, this increased
signiﬁcantly after migration of these populations to geo-
graphical areas where salt intake was high. Later on, the same
INTERSALT group reported a direct relationship of daily
urinary sodium excretion with blood pressure in a cross-
sectional investigation conducted in over 30 countries [20].
A Cochrane systematic review and meta-analysis of rando-
mised trials concluded that decreasing daily salt intake by
4.4 grams corresponding to 1.76 grams of sodium leads to a
small but statistically signiﬁcant fall in blood pressure in both
hypertensive and normotensive subjects [21]. In the Dietary
Approaches to Stop Hypertension (DASH) study, a typical
western diet was compared to a diet enriched in fruits,
vegetables, and low-fat dairy products, and within each
dietary group, the study subjects were assigned to eat food
with diﬀerent salt contents for a month [22]. In this study,
a dose-response relationship between dietary salt and
blood pressure levels was observed in subjects eating both
the DASH diet and the typical western diet. More recently,
the Prospective Urban Rural Epidemiology (PURE) study
examined 102,216 adults from 667 communities all over
the world to investigate the relationship between salt
intake and blood pressure and to clarify whether this rela-
tionship varies across diﬀerent geographical areas of the
world [23]. The study countries were categorized into four
diﬀerent income levels, and urinary sodium excretion was
estimated from a morning specimen and divided into
three levels. Sodium excretion was higher in men than in
women, in rural than in urban areas, and was inversely
related to gross national income. This study indicated that
for each 1-gram increment in urinary sodium excretion
corresponding to 2.5 grams of salt, systolic and diastolic
blood pressure increased by 2.1 and 0.8mmHg, respec-
tively. The association between urinary sodium and blood
pressure had a slope that was steeper in patients with
sodium excretion> 5 grams/day (corresponding to >12.5
grams of salt), in patients with hypertension, and in
elderly subjects. Overall, this study indicated that the pro-
portion of populations eating a low-sodium diet worldwide
is rather small and indicated that salt intake is only weakly
related to blood pressure. Thus, epidemiologic evidence
indicates that dietary salt aﬀects blood pressure, but its
inﬂuence seems to be small and restricted to subjects with
high salt consumption.
2.2. Dietary Salt and Cardiac Damage. Despite the evidence
supporting the contribution of salt to blood pressure regula-
tion, the potential beneﬁts of dietary salt restriction on
cardiovascular morbidity and mortality are uncertain. The
association of daily salt intake, as assessed by urinary sodium
excretion, with a composite outcome of cardiovascular events
and mortality was prospectively investigated in a 3-year
follow-up study [24]. An increased risk of the composite out-
come was associated with dietary sodium excretion of more
than 7 grams/day (corresponding to 17.5 grams of salt). Also,
the risk of death and cardiovascular events considered sepa-
rately was increased, and the association between dietary salt
and cardiovascular outcomes was strongest among hyperten-
sive patients. To notice, in this study, increased risk of cardio-
vascular events was also associated with daily sodium
excretion below 3 grams/day (corresponding to 7.5 grams
of salt), suggesting a J-shaped relationship. In another study
by the NutriCode group, the impact of dietary salt on cardio-
vascular outcomes was examined by the use of a complex
analysis technique [25]. Salt intake was quantiﬁed from data
obtained in surveys conducted in more than 60 diﬀerent
countries, and the eﬀects of salt on blood pressure and
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cardiovascular events were calculated with a meta-analysis.
This study reported a signiﬁcant dose-response relationship
between salt intake and cardiovascular events and estimated
that 1.65 million deaths for cardiovascular causes could
be ascribed to dietary salt worldwide. However, a recent
meta-analysis of seven prospective studies that compared
cardiovascular mortality in patients undergoing dietary
interventions to decrease salt consumption and patients
on a liberal diet did not report any beneﬁts of dietary
interventions [26]. This held true also when the study sub-
jects with normal blood pressure, hypertension, or heart
failure were considered separately. In summary, although
some important cumulative analyses suggest possible ben-
eﬁts of dietary salt restriction on cardiovascular morbidity
and mortality, deﬁnitive conclusions cannot be drawn.
3. Aldosterone and the Heart
Landmark studies have tested the eﬀects of aldosterone
antagonists on patients with systolic cardiac failure reporting
a highly signiﬁcant decrease in mortality as compared to
placebo [27] and supporting the view that elevated aldo-
sterone could be harmful to the heart. Later on, studies
conducted in patients with primary aldosteronism, essen-
tial hypertension, and diastolic heart failure have yielded
further evidence that elevated plasma aldosterone might
have untoward cardiac eﬀects [28] and might foreshadow
the onset of heart failure.
3.1. Primary Aldosteronism. Primary aldosteronism is associ-
ated with cardiac changes that might reﬂect the ability of
inappropriately elevated circulating aldosterone to cause
myocardial damage beyond that induced by high blood pres-
sure itself. Longitudinal retrospective studies have shown
that patients with primary aldosteronism have a greater risk
of atrial ﬁbrillation and coronary artery and cerebrovascular
disease than matched patients with essential hypertension
[29–32]. Also, and of greatest relevance, both surgical and
medical treatments of primary aldosteronism decrease
cardiovascular risk to the level of patients with essential
hypertension [10, 12, 30]. Cardiac ultrasound evaluations
have reported a greater increase in left ventricular mass
in primary aldosteronism than in other forms of hyperten-
sive disease [33, 34] suggesting inappropriate left ventricu-
lar hypertrophy for the hemodynamic load. In primary
aldosteronism, excess ventricular hypertrophy occurs in
conjunction with an abnormal pattern of ventricular ﬁlling
indicating diastolic dysfunction [35]. The cardiac ﬁndings
obtained in patients with primary aldosteronism were cor-
roborated by the demonstration that also patients with
familial hyperaldosteronism type 1 who have normal blood
pressure and elevated aldosterone have increased left
ventricular wall thickness and diastolic dysfunction in
comparison to matched normotensive patients [36].
Long-term observation after treatment of primary aldoste-
ronism showed that both adrenalectomy and spironolac-
tone caused a signiﬁcant decrease in ventricular mass
[34, 37] and that the extent of this decrease was directly
related to pretreatment plasma aldosterone levels [38].
3.2. Essential Hypertension and Left Ventricular Diastolic
Dysfunction. Because of the relevance of left ventricular
hypertrophy and diastolic dysfunction in patients with essen-
tial hypertension, the possible contribution of circulating
aldosterone to these cardiac changes has been extensively
investigated. Initial observations indicated that aldosterone
antagonists decrease left ventricular mass in patients with
essential hypertension and left ventricular hypertrophy
[37, 39] and improve myocardial function in hypertensive
patients with diastolic heart failure [40]. However, cross-
sectional evidence subsequently obtained in treatment-
naïve essential hypertensive patients indicated that plasma
aldosterone has no independent relationship with left ven-
tricular diastolic properties [41]. Consistently, a recent
study of hypertensive patients with diastolic dysfunction
reported no change in the ventricular ﬁlling pattern after
addition of spironolactone to previous antihypertensive
treatment, despite a signiﬁcant reduction in ventricular
mass [42]. It has to be considered that lack of association
between left ventricular diastolic dysfunction and plasma
aldosterone levels might be related to the limitation of
plasma aldosterone as a measure of the overall mineralo-
corticoid activity.
In 44 elderly patients with cardiac failure and preserved
ejection fraction, eplerenone improved left ventricular dia-
stolic function more than conventional treatment [43]. In
the Chronic Renal Impairment in Birmingham (CRIB II)
study, spironolactone improved markers of left ventricular
relaxation suggesting that aldosterone blockers might be
beneﬁcial in the management of patients with diastolic heart
failure [44], a hypothesis that was subsequently tested in two
important trials. In the Aldo-DHF trial, spironolactone
improved left ventricular diastolic function, but had no
eﬀects on maximal exercise capacity in patients with heart
failure and preserved ejection fraction [45]. Similarly, in a
subgroup of patients with heart failure and preserved sys-
tolic function included in the TOPCAT (Treatment of
Preserved Cardiac Function Heart Failure with an Aldoste-
rone Antagonist) trial, spironolactone signiﬁcantly reduced
a composite cardiovascular endpoint [46]. In summary,
plasma aldosterone levels seem to be marginally relevant
for left ventricular diastolic dysfunction in hypertensive
subjects, but the use of aldosterone antagonists in the
treatment of heart failure with preserved systolic function
has so far provided encouraging results.
4. The Contribution of Salt to Aldosterone-
Related Cardiac Damage
The hypothesis of an interplay between dietary salt and aldo-
sterone in causing cardiac damage was extensively supported
by the ﬁndings of animal studies [8, 9]. Some of the untoward
eﬀects of salt loading might depend on mineralocorticoid
receptor activation resulting from changes in the intracellular
redox state [47, 48]. Aldosterone aﬀects the redox potential of
diverse cell types increasing the generation of reactive oxygen
species, and this eﬀect is potentiated by exposure to high con-
centration of salt [49]. Therefore, an inappropriately high salt
status might sensitize mineralocorticoid receptors and
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explain why salt interacts with aldosterone in the induction
of cardiac damage.
In the clinical setting, observations on the contribution of
salt to aldosterone-mediated cardiac damage are restricted to
a few studies [50]. In a population study, a signiﬁcant and
independent correlation of the left ventricular mass index
with both 24-hour urinary sodium and aldosterone excretion
was reported by Jin et al. [51]. In 182 hypertensive patients
who were treated for 3 years with either angiotensin-
converting enzyme inhibitors or angiotensin II receptor
blockers, du Cailar et al. observed a direct relationship of
the percentage change in ventricular mass with the absolute
changes in urinary sodium and plasma aldosterone levels
[52]. In 90 essential hypertensive patients free of clinically
relevant cardiovascular complications, aldosterone levels
measured after intravenous saline load were found to be
independently related to left ventricular mass, suggesting
that limited ability of salt to modulate aldosterone produc-
tion could contribute to ventricular hypertrophy [53]. In
21 patients with primary aldosteronism, Pimenta et al. found
that urinary sodium independently predicts left ventricular
mass [54]. More recently, we have shown that an increased
left ventricular mass is associated with daily urinary sodium
excretion and plasma aldosterone levels in 65 patients with
primary aldosteronism [55]. Also, and most important, we
found that the extent of a reduction in left ventricular
mass obtained after either surgical or medical treatment
of primary aldosteronism was independently correlated
with the decrease in urinary sodium observed during treat-
ment. Thus, the hypothesis of an interaction between salt
and circulating aldosterone in causing damage to the heart
is currently supported by robust animal data and initial
clinical evidence.
5. Interplay of Salt and Aldosterone with
Calcium Metabolism
5.1. Relevance to the Bone. An interaction between compo-
nents of the renin-angiotensin-aldosterone system and
hormones involved in calcium homeostasis was initially sug-
gested in patients with salt-sensitive hypertension by Resnick
et al. [56] and has been reviewed in previous articles [13–15].
These authors reported for the ﬁrst time a signiﬁcant increase
in PTH levels in patients with primary aldosteronism. Later
on, a similar increase in serum PTH was demonstrated in
association with increased urinary calcium excretion [57],
lower serum calcium concentrations [58], and comparable
vitamin D levels [59] in patients with primary aldosteronism
in comparison to patients with essential hypertension. Con-
sistent with these ﬁndings, increased prevalence of osteopo-
rosis and increased risk of bone fracture have been reported
in patients with primary aldosteronism who were recruited
in diﬀerent geographical areas and were compared to
matched patients with essential hypertension [60, 61]. Also,
and most important, normalization of serum calcium and
PTH levels was reported to follow surgical treatment of
patients with aldosterone-producing adenomas [59] as well
as treatment with spironolactone of patients with bilateral
adrenal hyperplasia [58]. These ﬁndings are in agreement
with those of studies that demonstrated that administration
of spironolactone to aldosterone-salt-treated rats improves
cortical bone strength [62]. Consistently, treatment of pri-
mary aldosteronism was associated with signiﬁcant recovery
of the bone mineral density at diﬀerent skeletal sites from
decreased density that was detected at baseline [57]. These
observations support the hypothesis that an increased frac-
ture risk in patients with primary aldosteronism might result
from secondary hyper-PTH due to aldosterone-induced
hypercalciuria and subsequent hypocalcemia (Figure 1).
In support of the close interplay existing between PTH
and aldosterone, recent evidence indicates that type-1 PTH
receptors are expressed in aldosterone-producing adenomas
[63] and explains why PTH elevation might increase aldoste-
rone secretion. On the other hand, mineralocorticoid recep-
tors have been detected in the nuclei of parathyroid cells
indicating the possibility that aldosterone directly regulates
PTH production [63]. In this context, dietary salt consump-
tion could play an important role in as much as an inappro-
priate salt status causes activation of mineralocorticoid
receptors leading to an increased oxidative stress and pro-
moting tissue damage [64]. It was also suggested that salt
retention and extracellular ﬂuid expansion caused by ele-
vated circulating aldosterone could decrease sodium reab-
sorption in the distal tubule leading to an increased urinary
calcium excretion [65].
5.2. Relevance to the Heart. The interplay between salt, aldo-
sterone, and PTH has received robust support from experi-
mental animal studies. Treatment of rats with aldosterone
and 1% dietary salt increases urinary and intestinal calcium
excretion causing hypocalcemia and increased PTH secretion
[66]. In these rats, blockade of mineralocorticoid receptors
with the use of spironolactone decreases urinary and fecal
calcium losses restoring normal calcium homeostasis [67].
The same eﬀect of spironolactone was reported in patients
with chronic heart failure [68]. When healthy subjects are
exposed to a dietary salt excess, urinary calcium excretion
increases signiﬁcantly [69], an eﬀect that is signiﬁcantly more
pronounced in patients with primary aldosteronism than in
patients with essential hypertension [70]. On the other hand,
many studies have shown that aldosterone causes renal cal-
cium wasting in healthy subjects in the presence of dietary
salt excess [71] and data of the Styrian Hypertension Study
indicate that even in patients with essential hypertension,
the interaction between aldosterone, calcium, and PTH
varies depending upon the dietary salt intake [13].
In the setting of heart failure, aldosterone secretion is
increased as a result of renin-angiotensin axis activation
and causes salt and ﬂuid retention. The inappropriate eleva-
tion of aldosterone for the salt status increases urinary and
intestinal calcium losses with subsequent activation of PTH
production [72]. This explains why elevated PTH is fre-
quently associated with increased circulating aldosterone in
patients with heart failure [73] and supports the hypothesis
that PTH might concur with aldosterone in causing worsen-
ing of cardiac function in these patients [72]. Elevation of
PTH levels facilitates calcium uptake in many cell types
including cardiomyocytes, leading to mitochondrial calcium
4 International Journal of Endocrinology
overload. This, in turn, decreases the ability of the cell to
eﬃciently generate ATP thereby leading to cell death and
myocardial tissue damage [70] and inducing further wors-
ening of cardiac function [74]. In summary, both animal
and human studies support the hypothesis of a functional
interaction between aldosterone and PTH that could vary
according to the salt status. This interaction might have
an impact on bone structure and cardiac function in dif-
ferent disease conditions. Speciﬁcally designed studies with
aldosterone blockers or other types of interventions would
be needed to reach conclusive views on the pathophysio-
logic relevance of these mechanisms.
6. Conclusions
Robust scientiﬁc evidence demonstrates a relationship
between salt intake and blood pressure and supports the
beneﬁts of salt restriction in hypertension. Conversely, the
possible beneﬁts of dietary salt restriction on cardiovascular
outcomes are still debated because intervention studies and
cumulative analyses have not been able to provide thor-
oughly convincing results. Current evidence unquestionably
supports the view that elevated aldosterone causes cardiovas-
cular damage well beyond what could be expected just from
blood pressure elevation. Animal studies clearly indicate that
aldosterone-dependent cardiac damage is strictly dependent
on the salt status and this view is corroborated by the results
of some human studies. A close interaction between aldoste-
rone, calcium, and PTH has been demonstrated that is
dependent on the salt status both in healthy subjects and in
disease states. This complex interplay of salt with aldosterone
and PTH might contribute to the development and
progression of organ damage in patients with primary aldo-
steronism or primary hyper-PTH, in patients with heart
failure, and in subjects with dietary salt excess. These obser-
vations might have important therapeutic implications
inasmuch as dietary salt restriction, aldosterone blockers, cal-
cimimetic drugs, and PTH receptor blockers might prove
beneﬁcial for cardiovascular and bone protection in these
conditions. The eﬀects of all these interventions will have to
be tested in appropriately designed studies.
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